DK1272169T3 - Anvendelse af 13-hode som regulator for vaskular biokompatibilitet og som inhibitor for cellulær hyperplasi - Google Patents

Anvendelse af 13-hode som regulator for vaskular biokompatibilitet og som inhibitor for cellulær hyperplasi

Info

Publication number
DK1272169T3
DK1272169T3 DK01923421T DK01923421T DK1272169T3 DK 1272169 T3 DK1272169 T3 DK 1272169T3 DK 01923421 T DK01923421 T DK 01923421T DK 01923421 T DK01923421 T DK 01923421T DK 1272169 T3 DK1272169 T3 DK 1272169T3
Authority
DK
Denmark
Prior art keywords
vessel wall
biocompatibility
regulator
inhibitor
head
Prior art date
Application number
DK01923421T
Other languages
Danish (da)
English (en)
Inventor
David Croftlea Horrobin
Michael R Buchanan
Original Assignee
1411198 Ontario Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1411198 Ontario Ltd filed Critical 1411198 Ontario Ltd
Application granted granted Critical
Publication of DK1272169T3 publication Critical patent/DK1272169T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
DK01923421T 2000-04-07 2001-04-06 Anvendelse af 13-hode som regulator for vaskular biokompatibilitet og som inhibitor for cellulær hyperplasi DK1272169T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002304906A CA2304906A1 (en) 2000-04-07 2000-04-07 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
PCT/CA2001/000477 WO2001076568A2 (en) 2000-04-07 2001-04-06 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia

Publications (1)

Publication Number Publication Date
DK1272169T3 true DK1272169T3 (da) 2009-03-23

Family

ID=4165841

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01923421T DK1272169T3 (da) 2000-04-07 2001-04-06 Anvendelse af 13-hode som regulator for vaskular biokompatibilitet og som inhibitor for cellulær hyperplasi

Country Status (13)

Country Link
US (3) US20030153621A1 (de)
EP (1) EP1272169B1 (de)
KR (1) KR100775678B1 (de)
AT (1) ATE414510T1 (de)
AU (1) AU2001250194A1 (de)
CA (1) CA2304906A1 (de)
DE (1) DE60136618D1 (de)
DK (1) DK1272169T3 (de)
HK (1) HK1050482A1 (de)
MX (1) MXPA02009831A (de)
NZ (1) NZ522242A (de)
TW (1) TWI287447B (de)
WO (1) WO2001076568A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473708B2 (en) * 1996-02-15 2009-01-06 Jean Gosselin Agents with leukotriene B4-like antiviral (enveloped RNA) activities
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
FR2856304B1 (fr) * 2003-06-20 2006-03-03 Natural Product Consulting Composition pour la prevention des infections du systeme urinaire
WO2005013908A2 (en) * 2003-08-05 2005-02-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer’s disease and retinal degeneration
AU2005210326B2 (en) * 2004-02-09 2009-10-22 Nissan Chemical Industries, Ltd. Drug for inhibiting vascular intimal hyperplasia
WO2005102309A2 (en) * 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
WO2006065916A1 (en) * 2004-12-14 2006-06-22 Alcon, Inc. Method of treating dry eye disorders using 13(s)-hode and its analogs
WO2006137435A1 (ja) * 2005-06-22 2006-12-28 National University Corporation Gunma University Gタンパク質共役型受容体g2aの作動薬、及びg2a活性調節薬のスクリーニング方法
US8040207B2 (en) 2009-01-15 2011-10-18 Infineon Technologies Ag MEMS resonator devices with a plurality of mass elements formed thereon
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
GB0907601D0 (en) * 2009-05-01 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
ES2417279B2 (es) * 2012-02-01 2014-04-07 Universidad De Cadiz Uso de oxilipinas y sus derivados como agentes antiinflamatorios
CN109061137A (zh) * 2018-09-05 2018-12-21 重庆医科大学 13(s)-hode水平作为心血管疾病检测指标的用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
JPH0615469B2 (ja) * 1984-05-09 1994-03-02 テルモ株式会社 脂肪輸液剤
US4528902A (en) * 1984-06-18 1985-07-16 Hughes Company, Inc. Pod vegetable processing machine with pod deflecting device
US4871768A (en) * 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
CA1282727C (en) * 1985-07-11 1991-04-09 Michael R. Buchanan Chemorepellant compound
HU199444B (en) * 1985-09-10 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom
JPH0710776B2 (ja) * 1986-01-13 1995-02-08 株式会社ツムラ アンジオテンシンｉ転換酵素阻害剤
DE3615710A1 (de) * 1986-05-09 1987-11-26 Hoechst Ag Zubereitungen fuer die synthese von prostaglandinen und hydroxyfettsaeuren in biologischen systemen
FR2626583B1 (fr) * 1988-01-29 1991-03-15 Bioeurope Procede de preparation enzymatique d'oligodextranes utiles dans la fabrication de substituts du sucre, et nouveaux oligodextranes
US5023100A (en) * 1988-05-02 1991-06-11 Kabi Vitrum Ab Fish oil
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
CH676909A5 (de) * 1988-12-23 1991-03-28 Nestle Sa
US5015483A (en) * 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5015485A (en) * 1989-05-30 1991-05-14 Nabisco Brands, Inc. Dog biscuits having a coating containing an inorganic pyrophosphate
DE4000397A1 (de) * 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
DK0457950T3 (da) * 1990-05-23 1994-03-07 Nestle Sa Anvendelse af stearidonsyre til behandling af inflammatorisk betingede sygdomme
US5102912A (en) * 1990-10-24 1992-04-07 Kanoldt Arzneimittel Gmbh Hydroxyoctadecadienic acid for the treatment of estrogen-dependent disease
SE9101642D0 (sv) * 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
JPH0649479A (ja) * 1992-07-28 1994-02-22 Maruha Corp ω−３不飽和脂肪酸系化合物の安定化法
JPH07291862A (ja) * 1994-04-28 1995-11-07 Tamanoisu Kk 抗腫瘍剤及びその製造法
FR2746035B1 (fr) * 1996-03-15 1998-06-12 Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications
US6160141A (en) * 1997-02-18 2000-12-12 Seidel; Michael C. Synthesis of conjugated eicosadienoic acid
US5891802A (en) * 1997-07-23 1999-04-06 Advanced Micro Devices, Inc. Method for fabricating a metallization stack structure to improve electromigration resistance and keep low resistivity of ULSI interconnects
CA2303935A1 (en) * 1997-10-15 1999-04-22 City Of Hope 12(s)-hete receptor blockers
SE9800729L (sv) * 1998-03-06 1999-09-07 Scotia Lipidteknik Ab Ny topikal formulering I
US6077525A (en) * 1998-04-10 2000-06-20 The George Washington University Use of conjugated linoleic acids
US6710032B1 (en) * 1998-05-12 2004-03-23 University Of Maryland In situ formation of CLA
WO1999059562A2 (en) * 1998-05-20 1999-11-25 City Of Hope Method of treating or preventing abnormal cardiac cell growth by inhibiting the 12-lipoxygenase pathway
US6617122B1 (en) * 1999-03-15 2003-09-09 Xenon Genetics, Inc. Process for identifying modulators of ABC1 activity
WO2001003688A2 (en) * 1999-07-09 2001-01-18 Pharmacia Corporation Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds
US6436993B1 (en) * 1999-07-13 2002-08-20 The Salk Institute For Biological Studies Use of RAR antagonists as modulators of hormone mediated processes
US6211819B1 (en) * 1999-08-27 2001-04-03 Motorola, Inc. Mobile station location determination in a radio communication system
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia

Also Published As

Publication number Publication date
KR20030007495A (ko) 2003-01-23
DE60136618D1 (de) 2009-01-02
TWI287447B (en) 2007-10-01
US7202276B2 (en) 2007-04-10
CA2304906A1 (en) 2001-10-07
NZ522242A (en) 2004-12-24
HK1050482A1 (en) 2003-06-27
US20020028848A1 (en) 2002-03-07
AU2001250194A1 (en) 2001-10-23
KR100775678B1 (ko) 2007-11-09
US20030153621A1 (en) 2003-08-14
WO2001076568A3 (en) 2002-09-26
ATE414510T1 (de) 2008-12-15
EP1272169B1 (de) 2008-11-19
EP1272169A2 (de) 2003-01-08
WO2001076568B1 (en) 2002-10-24
US20070197644A1 (en) 2007-08-23
MXPA02009831A (es) 2004-09-06
WO2001076568A2 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
DK1272169T3 (da) Anvendelse af 13-hode som regulator for vaskular biokompatibilitet og som inhibitor for cellulær hyperplasi
BR9811099A (pt) Inibidores de urocinase
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
AU2721402A (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
DK1420801T3 (da) Anvendelse af fucaner til behandling af adhæsioner, arthritis og psoreasis
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
EP2260835A3 (de) Zusammensetzung zur Proteasomhemmung
PT1117440E (pt) Composicoes farmaceuticas que contem paclitaxel
DK1239857T3 (da) Dual-release-præparater af en cyclooxygenase-2-hæmmer
JO2473B1 (en) Pyrazoles as inhibitors of tumor necrosis factor
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
AR024138A1 (es) Inhibidores de la proliferacion celular
DE60144514D1 (de) Verwendung von il-18 inhibitoren
WO2003106381A3 (en) ADAM 10 HUMAN INHIBITORS
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
AU2003293555A1 (en) 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ATE424893T1 (de) Behandlung und vorbeugung von insulin- produzierende zelltransplantatabstossung
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
IT1320080B1 (it) Composizione per uso farmaceutico o dietetico.
WO2002004409A3 (en) Tetrahydrobenzothiazole analogues as neuroprotective agents
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
DK1079843T3 (da) Anvendelse af a1beta1 integrinreceptorinhibitorer og TFG beta1 inhibitorer til behandling af nyresygdom
AU6469401A (en) Pharmaceutically active compounds and methods of use
NO20065898L (no) 1-heterocyklyl-1,5-dihydro-pyrido[3,2-b]indol-2-oner